Novel Stx1-targeting Fabs, FabB6:Stx1 and FabC8:Stx1, differentially neutralize Shiga toxin in renal epithelial and endothelial cells
Background
Hemolytic Uremic Syndrome (HUS) is a severe, life-threatening complication primarily caused by Shiga toxin (Stx)-producing Escherichia coli (STEC). Stx leads to systemic endothelial damage, particularly affecting the kidneys, resulting in microangiopathic hemolytic anemia and acute kidney injury. Current therapeutic strategies for HUS are largely supportive, with no specific antitoxin therapies widely available. While recombinant antibody development has focused on neutralizing the Stx2 subtype, many STEC strains also produce Stx1, either alone or with Stx2, highlighting a critical unmet need for comprehensive antitoxin treatments targeting both toxin types.
Study Design
Researchers characterized two novel, fully human recombinant Fab antibodies, FabB6:Stx1 and FabC8:Stx1, selected from a synthetic library using phage display technology. These Fabs were designed to specifically target Shiga toxin 1 (Stx1). Their binding specificity and neutralizing activity were rigorously evaluated in vitro using Vero cells, human proximal tubular epithelial (HK-2) cells, and primary human glomerular endothelial cells (HGEC). Cells were exposed to supernatants derived from HUS-associated STEC isolates. The study also compared the Stx1-specific Fabs' efficacy alongside previously characterized anti-Stx2 antibodies (FabC11:Stx1/Stx2 and FabF8:Stx2) to assess complementary protection.
Results
Both novel Fabs, FabB6:Stx1 and FabC8:Stx1, demonstrated high specificity and nanomolar affinity for Stx1, confirming their potent binding capabilities. Crucially, their neutralizing activity against Stx1 exhibited cell-type-dependent profiles across the tested renal cell models. When evaluated in combination with existing anti-Stx2 antibodies (FabC11:Stx1/Stx2 and FabF8:Stx2), the Stx1-specific Fabs provided complementary protection against the cytotoxic effects of clinical STEC isolates. This suggests a broader neutralizing capacity against the complex toxin mixtures produced by STEC. The findings underscore the importance of targeting Stx1 to achieve more comprehensive antitoxin coverage, especially given the prevalence of Stx1-producing STEC strains.
FabC8:Stx1 consistently showed superior and more robust neutralization of Stx1 in HK-2 cells compared to FabB6:Stx1, indicating differential efficacy based on the cellular environment.
Why It Matters
This research significantly advances the development of comprehensive antitoxin therapies for STEC-associated diseases, particularly Hemolytic Uremic Syndrome (HUS). By introducing effective Stx1-targeting recombinant antibodies, the therapeutic landscape expands beyond the current Stx2-centric focus. This is crucial because many clinical STEC isolates produce Stx1, either alone or in conjunction with Stx2, meaning a significant portion of HUS cases may not be adequately addressed by Stx2-specific treatments alone. Integrating Stx1-specific Fabs into multi-toxin neutralization strategies could lead to more robust and broadly effective treatments, potentially reducing the severity and incidence of HUS. While currently preclinical, these findings lay the groundwork for future in vivo studies and, ultimately, human clinical trials for a much-needed specific HUS therapy.